Evidence map›Paper›PMID 32577626›Full record

ArticleCell reports. Medicine2020

Persistence of HIV-1 Env-Specific Plasmablast Lineages in Plasma Cells after Vaccination in Humans.

Madhubanti Basu, Michael S Piepenbrink, Czestochowa Francois, Fritzlaine Roche, Bo Zheng, David A Spencer, Ann J Hessell, Christopher F Fucile, Alexander F Rosenberg, Catherine A Bunce and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports. Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Madhubanti BasuInfectious Diseases Division, University of Alabama at Birmingham, Birmingham, AL, USA.
Michael S PiepenbrinkInfectious Diseases Division, University of Alabama at Birmingham, Birmingham, AL, USA.
Czestochowa FrancoisSchool of Medicine, University of Rochester, Rochester, NY, USA.
Fritzlaine RocheSchool of Medicine, University of Rochester, Rochester, NY, USA.
Bo ZhengInfectious Diseases Division, University of Rochester, Rochester, NY, USA.
David A SpencerOregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA.
Ann J HessellOregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA.
Christopher F FucileInformatics Institute, University of Alabama at Birmingham, Birmingham, AL, USA.
Alexander F RosenbergDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Catherine A BunceInfectious Diseases Division, University of Rochester, Rochester, NY, USA.
Jane LiesveldDivision of Hematology/Oncology, University of Rochester, Rochester, NY, USA.
Michael C KeeferInfectious Diseases Division, University of Rochester, Rochester, NY, USA.
James J KobieInfectious Diseases Division, University of Alabama at Birmingham, Birmingham, AL, USA.
University of Rochester · USUniversity of Alabama at Birmingham · USOregon National Primate Research Center · US

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
University of Rochester HIV/AIDS Clinical Trials Unit Administrative SupplementUM1AI069511 · NIAID · UNIVERSITY OF ROCHESTER · PI Paul R Bohjanen, MICHAEL C KEEFER · 2012 to 2026
$25.7M
Virology/Immunology CoreP30AI078498 · NIAID · UNIVERSITY OF ROCHESTER · PI DEWHURST, STEPHEN · 2008 to 2018
$14.6M
Targeting tonsillar B cells for the induction of effective mucosal immunity to HIVR01DE027245 · NIDCR · UNIVERSITY OF ROCHESTER · PI KOBIE, JAMES J · 2017 to 2021
$3.7M
Targeting IgM Memory to Establish Protective B Cell Responses to HIVR01AI117787 · NIAID · UNIVERSITY OF ROCHESTER · PI KOBIE, JAMES J · 2015 to 2018
$2.7M
The Origin and Fate of Human HIV-Specific Plasma Cells Following VaccinationR21AI116285 · NIAID · UNIVERSITY OF ROCHESTER · PI KOBIE, JAMES J · 2015 to 2016
$422k
Developing appropriate risk reduction interventions for pre-teensR21MH083308 · NIMH · WITS HEALTH CONSORTIUM (PTY), LTD · PI GRAY, GLENDA E, SIKKEMA, KATHLEEN J · 2008 to 2009
$331k
NIAID NIH HHS P30 AI078498NIAID NIH HHS R01 AI117787NIAID NIH HHS R21 AI116285NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI069511NIDCR NIH HHS R01 DE027245NIMH NIH HHS R21 MH083308
6 · The paper itself

Abstract

Induction of persistent HIV-1 Envelope (Env) specific antibody (Ab) is a primary goal of HIV vaccine strategies; however, it is unclear whether HIV Env immunization in humans induces bone marrow plasma cells, the presumed source of long-lived systemic Ab. To define the features of Env-specific plasma cells after vaccination, samples were obtained from HVTN 105, a phase I trial testing the same gp120 protein immunogen, AIDSVAX B/E, used in RV144, along with a DNA immunogen in various prime and boost strategies. Boosting regimens that included AIDSVAX B/E induced robust peripheral blood plasmablast responses. The Env-specific immunoglobulin repertoire of the plasmablasts is dominated by VH1 gene usage and targeting of the V3 region. Numerous plasmablast-derived immunoglobulin lineages persisted in the bone marrow >8 months after immunization, including in the CD138

Indexed as

AIDS VaccinesAntibody SpecificityCell LineageCells, CulturedCell Survivalenv Gene Products, Human Immunodeficiency VirusHEK293 CellsHIV-1HIV InfectionsHumansPlasma CellsTHP-1 CellsVaccinationAIDS VaccinesAIDSVAX B-Eenv Gene Products, Human Immunodeficiency Virus

Identifiers

PMID32577626
PMCPMC7311075
OpenAlexW3026065405

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.